Drugs / certepetide
certepetide
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06216561 | Nov 2023 → Jun 2024 | appendix cancer, ovarian carcinoma, peritoneal carcinomatosis | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 1 | NCT03517176 | Jul 2018 → Jun 2020 | pancreatic ductal adenocarcinoma | Lisata Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06592664 | Jan 2030 → Jan 2035 | pancreatic ductal adenocarcinoma | Lisata Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05052567 | Oct 2021 → Jun 2024 | malignant pancreatic neoplasm | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT05121038 | Oct 2021 → Sep 2025 overdue | colon carcinoma, malignant pancreatic neoplasm | Anup Kasi | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06261359 | Mar 2024 → Apr 2025 overdue | pancreatic ductal adenocarcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05712356 | May 2023 → Apr 2026 | gallbladder carcinoma, intrahepatic cholangiocarcinoma | Lisata Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05042128 | Apr 2022 → Jun 2025 | pancreatic ductal adenocarcinoma | Australasian Gastro-Intestinal Trials Group | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | certepetide | “Drug: certepetide” NCT05712356 ↗ |
| Known as | CEND-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05052567 ↗ |
| Known as | Certepetida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315026 ↗ |
| Known as | LSTA1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05042128 ↗ |
| Modality | Peptide | “CEND-1 is a novel cyclic peptide” PMID 35803294 ↗ Jul 2022 |
| Route | Intravenous | “CEND-1 will be provided as concentrate for solution to be administered via IV injection.” NCT03517176 ↗ |